Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.
Headquarters
United States of America
Address
1490 Obrien Dr Ste A, Menlo Park, California, 94025-1499
Website
www.fortyseveninc.com/
Telephone
1 650 3524150
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Forty Seven Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| 5F9 for the treatment of solid tumors and AML MDS |
| 5F9 + Rituximab for the treatment of B-Cell NHL |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Forty Seven Inc | Legend Biotech Corp | Ambrx Biopharma Inc | Exo Therapeutics Inc | Immunitas Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Menlo Park | Somerset | La Jolla | Cambridge | Waltham |
| State/Province | California | New Jersey | California | Massachusetts | Massachusetts |
| No. of Employees | 68 | 2,900 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark McCamish | President; Director; Chief Executive Officer | Executive Board | 2017 | 67 |
| Ann D Rhoads | Chief Financial Officer | Senior Management | - | - |
| Chris H Takimoto | Chief Medical Officer | Senior Management | - | - |
| Qinghai Zhao | Vice President - Technical Development and Manufacturing | Senior Management | - | - |
| Jens-Peter Volkmer | Vice President - Research and Early Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer